Company profile
Acurx Pharmaceuticals, Inc.
NASDAQ:ACXPBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IBEZAPOLSTAT | phase2 | — | 2 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04247542 | phase2 | completed | 2020-03-06 | 2023-10-03 | Acurx Pharmaceuticals Inc. | ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection |
| NCT07513285 | phase2 | recruiting | 2026-08-06 | 2027-09-29 | Acurx Pharmaceuticals Inc. | ACX-362E [Ibezapolstat] for Oral Treatment of Recurrent Clostridioides Difficile Infection |
FDA applications (0)
No records yet.